adalimumab

Home
Ligands
adalimumab

GtoPdb Ligand ID: 4860

Synonyms: D2E7 [6] | Humira®

adalimumab is an approved drug (FDA (2002), EMA (2003))

Comment: Adalimumab is an anti-TNFα monoclonal antibody with immunosuppresive activity [6]. It was the first fully human monoclonal antibody drug approved by the FDA.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

X-ray structures of the apo and TNFα-bound Fab fragment of adalimumab have been deposited to the RCSB Protein Data Bank (IDs 4NYL and 3WD5 respectively).

Biosimilars:

Name	Trade name	Company	Clinical Phase	Indications	References
adalimumab-atto; ABP 501	Amjevita; Amgevita	Amgen	Approved (2016 FDA, 2017 EMA)	As per reference agent	[8]
adalimumab-adbm; BI 695501	Cyltezo	Boehringer Ingelheim	Approved (2017 FDA and EMA)	As per reference agent
ZRC-3197	Exemptia	Cadila Healthcare	Approved (2015 India)	Rheumatoid arthritis	[2,4]
adalimumab-bwwd; SB5	Hadlima	Samsung Bioepis	Approved (2019 FDA)	As per originator reference agent
adalimumab-aacf: MSB11022	Idacio; Kromeya	Fresenius Kabi	Approved (2019 EMA, 2022 FDA)	As per originator reference agent
BCD-057		Biocad	Ph 3 (NCT02762955)	Plaque psoriasis
adalimumab-adaz; GP2017	Hyrimoz; Hefiya; Halimatoz	Sandoz	Approved (2018 EMA and FDA)	As per originator reference agent. The FDA approved this as an an interchangeable biosimilar to Humira in 2024.	[7]
M923		Momenta Pharmaceuticals	Ph 3 (NCT02581345)	Plaque psoriasis, rheumatoid arthritis
adalimumab-fkjp; MYL-1401A; FKB327	Hulio	Mylan, Fujifilm Kyowa Kirin Biologics	Approved (2018 EMA, 2020 FDA)	As per originator reference agent	[9,12]
adalimumab-afzb; PF-06410293	Abrilada; Amsparity	Pfizer	Approved (2019 FDA, 2020 EMA)	As per originator reference agent
adalimumab-aaty; CT-P17	Yuflyma	Celltrion Healthcare Hungary Kft	Approved (2021 EMA, 2023 FDA)	As per originator reference agent
adalimumab-aqvh; CHS-1420	Yusimry	Coherus BioSciences	Approved (2021 FDA)	As per originator reference agent
IBI303		Innovent Biologics	Ph 3 (NCT02893254)	Active ankylosing spondylitis	[1]
adalimumab-ryvk; AVT02	Hukyndra; Libmyris; Simlandi	Alvotech/DKSH/Stada Arzneimittel/Teva	Approved (2021 EMA; 2024 FDA)	As per originator reference agent. FDA approved this as an interchangeable biosimilar to Humira.